Sophie Amsellem-Bosq

Sophie has more than 20 years’ experience in cell and gene therapy across the entire value chain from discovery through clinical development and manufacturing, up to bedside. She joins InnoSkel from advising and sharing her expertise with cell and gene therapy biotech companies and venture capital funds. Prior to this, Sophie served as Global CAR-T Program Director at international pharmaceutical company Servier, where she led the company’s allogenic CAR-T pipeline development strategy and the cross-functional coordination of related activities. She was Head of Cell and Gene Therapy Manufacturing Business Unit at Yposkesi (formerly Généthon Bioprod), a leading CDMO for gene therapy viral vector manufacturing, where she implemented from scratch the development and manufacturing of genetically modified cell drug products. Sophie has held several multi-faceted positions at various leading institutions such as Gustave Roussy Cancer Centre, Ambroise Paré Hospital and INSERM. She holds a PharmD from University Paris XI, Châtenay-Malabry and a PhD in Blood Cell Biology from University Paris VII, Paris.

At InnoSkel, Sophie is responsible for overseeing the definition and deployment of all CMC development and manufacturing strategic activities within the Company’s integrated platform.